Business Description
BriaCell Therapeutics Corp
NAICS : 325410
SIC : 3741
ISIN : CA10778Y1043
Share Class Description:
STU:8BT: Ordinary Shares - NewTotal Employee Number:
4Description
BriaCell Therapeutics Corp is a clinical-stage biotechnology company focused on developing immunotherapies for cancer treatment, particularly breast cancer. The company's targeted immunotherapy program, Bria-IMT, is a targeted cell-based immunotherapy in end-stage clinical trials aiming to improve outcomes for patients with breast cancer. BriaCell also develops Bria-OTS, personalized off-the-shelf immunotherapies for breast and prostate cancer. BriaCell is involved in clinical collaborations to explore combination therapies for enhanced cancer treatment options.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | No Debt | |||||
Equity-to-Asset | 0.89 | |||||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 36.7 | |||||
3-Year EPS without NRI Growth Rate | 22.6 | |||||
3-Year FCF Growth Rate | 16.5 | |||||
3-Year Book Growth Rate | -53.6 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 70.69 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
14-Day RSI | 18.63 | |||||
12-1 Month Momentum % | -68.69 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 7.07 | |||||
Quick Ratio | 7.07 | |||||
Cash Ratio | 6.35 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -163.5 | |||||
Shareholder Yield % | -117.31 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -161.06 | |||||
ROA % | -136.42 | |||||
ROIC % | -1822.48 | |||||
3-Year ROIIC % | -1098.87 | |||||
ROC (Joel Greenblatt) % | -10446.68 | |||||
ROCE % | -166.13 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 5 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 1.22 | |||||
Price-to-Tangible-Book | 1.23 | |||||
EV-to-EBIT | -0.35 | |||||
EV-to-EBITDA | -0.36 | |||||
EV-to-Forward-Revenue | 0.07 | |||||
EV-to-FCF | -0.36 | |||||
| Price-to-Net-Current-Asset-Value | 1.31 | |||||
| Price-to-Net-Cash | 1.49 | |||||
Earnings Yield (Greenblatt) % | -285.71 | |||||
FCF Yield % | -87.63 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
BriaCell Therapeutics Corp Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -10.46 | ||
| Beta | 0.7838 | ||
| 3-Year Sharpe Ratio | -1.46 | ||
| 3-Year Sortino Ratio | -1.58 | ||
| Volatility % | 73.27 | ||
| 14-Day RSI | 18.63 | ||
| 14-Day ATR (€) | 0.000007 | ||
| 20-Day SMA (€) | 5.56 | ||
| 12-1 Month Momentum % | -68.69 | ||
| 52-Week Range (€) | 5.25 - 17.44 | ||
| Shares Outstanding (Mil) | 8.7 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
BriaCell Therapeutics Corp Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
BriaCell Therapeutics Corp Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| First quarter earnings results for 2027 | 2026-12-11 | In 152 days | ||
| Annual report for 2026 | 2026-10-16 | In 96 days | ||
| Third quarter earnings results for 2026 | 2026-06-09 | 5.56 (+0.00%) | ||
| Second quarter earnings results for 2026 | 2026-03-10 | 5.56 (+0.00%) | ||
| General meeting for 2026 | 2026-03-05 11:00 | 5.56 (+0.00%) | ||
| First quarter earnings results for 2026 | 2025-12-11 | 5.56 (+0.00%) | ||
| Annual report for 2025 | 2025-10-16 | 5.56 (+0.00%) | ||
| 0.1:1 Stock Split | 2025-08-25 | 5.56 (+0.00%) | ||
| Third quarter earnings results for 2025 | 2025-06-16 | 30.25 (+0.00%) | ||
| Second quarter earnings results for 2025 | 2025-03-12 | 32.70 (+5.65%) |
Show
Entries
BriaCell Therapeutics Corp Frequently Asked Questions
What is BriaCell Therapeutics Corp(STU:8BT)'s stock price today?
The current price of STU:8BT is €5.56. The 52 week high of STU:8BT is €17.44 and 52 week low is €5.25.
When is next earnings date of BriaCell Therapeutics Corp(STU:8BT)?
The next earnings date of BriaCell Therapeutics Corp(STU:8BT) is 2026-09-09 Est..
Does BriaCell Therapeutics Corp(STU:8BT) pay dividends? If so, how much?
BriaCell Therapeutics Corp(STU:8BT) does not pay dividend.
Press Release
Articles on BriaCell Therapeutics Corp
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers